1-(4-Isopropylphenyl)guanidine | 751442-57-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-Isopropylphenyl)guanidine
• 英文别名: 2-(4-propan-2-ylphenyl)guanidine
• CAS: 751442-57-6
• 化学式: C₁₀H₁₅N₃
• 分子量: 177.249
• InChiKey: LPOFCJMZSWBTHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(4-Isopropylphenyl)guanidine 、 3-(Dimethylamino)-1-pyrazolo[1,5-b]pyridazin-3-ylprop-2-en-1-one 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 GW805758
  参考文献：
  名称：

  Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors

  摘要：

  A novel series of pyrazolo[1,5-b]pyridazines have been synthesized and identified as cyclin dependant kinase inhibitors potentially useful for the treatment of solid tumors. Modification of the hinge-binding amine or the C(2)- and C(6)-substitutions on the pyrazolopyridazine core provided potent inhibitors of CDK4 and demonstrated enzyme selectivity against VEGFR-2 and GSK3beta.

  DOI：

  10.1016/j.bmcl.2008.09.069

文献信息

• POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE
  申请人：Elysium Therapeutics, Inc.

  公开号：US20170100390A1

  公开（公告）日：2017-04-13

  The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.

  这项发明提供了用于治疗或预防疼痛的组合物和方法。该发明提供了构造物，通过指定的胃肠酶在口服时直接或间接地水解构造物释放阿片类物质。该发明中构造物中的胃肠酶介导的阿片类物质释放被设计为在体内通过饱和或抑制机制在摄入过量时减弱。该发明进一步提供了对口服过量、化学篡改和通过非口服途径滥用高度抵抗的构造物。
• Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH
  申请人：Wooley Karen L.

  公开号：US20150346099A1

  公开（公告）日：2015-12-03

  Described herein are optical agents, including compositions, preparations and formulations, for monitoring the pH of a fluid. Optical agents described herein include photonic nanostructures and nanoassemblies including supramolecular structures, such as shell cross-linked micelles, that incorporate at least one linking group comprising one or more photoactive moieties that provide functionality as exogenous agents for a range of pH monitoring applications. Optical agents described herein comprise supramolecular structures having linking groups imparting useful optical and structural functionality. In an embodiment, for example, the presence of linking groups function to covalently cross link polymer components to provide a cross-linked shell stabilized supramolecular structure, and also impart useful optical functionality, for example by functioning as a fluorophore.

  本文描述了光学试剂，包括用于监测流体pH的组成物、制剂和配方。这里描述的光学试剂包括光子纳米结构和纳米组装体，包括超分子结构，如壳交联胶囊，其包含至少一个含有一个或多个光活性基团的连接基团，作为外源试剂在各种pH监测应用中发挥功能。这里描述的光学试剂包括具有连接基团的超分子结构，赋予有用的光学和结构功能。例如，在一个实施例中，连接基团的存在可以通过共价交联聚合物组分来提供一个交联壳稳定的超分子结构，并且还可以赋予有用的光学功能，例如作为荧光团。
• COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS
  申请人：THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH

  公开号：US20160159754A1

  公开（公告）日：2016-06-09

  Described herein are compounds, compositions, and methods of their use for the treatment of cystic fibrosis.

  本文描述了用于治疗囊性纤维化的化合物、组成物及其使用方法。
• Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
  申请人：Emory University

  公开号：US10568889B2

  公开（公告）日：2020-02-25

  The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

  本公开涉及前列腺素受体EP2拮抗剂、衍生物、组合物及其相关方法。在某些实施方案中，本公开涉及通过向有需要的受试者施用包含本文公开的化合物的药物组合物来治疗或预防 EP2 受体激活具有生理作用的病症和疾病的方法，这些病症和疾病包括但不限于脑损伤、炎症性疾病、癫痫发作后的神经损伤、疼痛、子宫内膜异位症、癌症、类风湿性关节炎、皮肤炎症、血管炎症、结肠炎和神经系统疾病。
• Inhibitors of growth factor activation enzymes
  申请人：Janetka James W.

  公开号：US11130780B2

  公开（公告）日：2021-09-28

  The present invention generally relates to compounds that are useful for inhibiting one or more of hepatocyte growth factor activator, matriptase, hepsin, Factor Xa, or thrombin. The present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.

  本发明一般涉及可用于抑制一种或多种肝细胞生长因子激活剂、淀粉酶、肝素、Xa因子或凝血酶的化合物。 本发明还涉及使用抑制剂化合物的各种方法，包括通过向有需要的受试者施用有效量的抑制剂来治疗恶性肿瘤、恶性肿瘤前期病症或癌症。